Partner David Rosen, who chairs the firm’s FDA regulatory practice, was quoted in a Law360 article, “FDA Focus: What Foley & Lardner’s Practice Chair is Watching,” about litigation and regulation he’s watching, the skills he looks for when hiring an FDA lawyer and the one FDA policy he’d change if he had a magic wand.
Rosen said the firm does a lot of work with compliance and enforcement, especially with data integrity issues. He also said he’s always been a “stickler” about making sure products meet appropriate standards of identity, strength, quality and purity at the time of use.
People
Related News
06 February 2025
In the News
Vanessa Miller Assesses Panama Canal Discourse
Foley & Lardner LLP partner Vanessa Miller commented in SupplyChainBrain article, "The Fight for Control of the Panama Canal," lending important context to the recent headlines over the important waterway.
06 February 2025
In the News
Gregory Husisian Weighs in on Suspension of De Minimis Trade Exemption
Foley & Lardner LLP partner Gregory Husisian offered context on President Trump's recent trade actions on China in The Wall Street Journal article, "Why Trump Is Closing a Trade Exemption for China."
04 February 2025
In the News
Andrew Wronski on Tariff Fluidity – 'Keep on top of the issues'
Foley & Lardner LLP partner Andrew Wronski assessed the evolving shift in U.S. trade policy in the Milwaukee Business Journal article, "Trump tariffs won't disappear — so how should Wisconsin businesses prepare?"